Abstract

Abstract Background Endoscopic sleeve gastroplasty (ESG) is emerging as an innovative approach to treating obesity. It provides a bridge between surgical and medical treatments for obesity. Nevertheless, the majority of reports on ESG originate from Western countries, and there is a lack of data from Asian nations. This study aims to share our pioneering experience with this novel technique in Asia. Materials and Methods We enrolled obese patients with a body mass index greater than 27 kg/m2 who were at least 20 years old. ESG was conducted following a comprehensive preoperative assessment. Following the procedure, patients were scheduled for regular outpatient department follow-up appointments at 7 days, 1 month, 2 months, 3 months, and then every 3 months up to 18 months postoperation. Body weight and any adverse events were documented during each follow-up visit. Results A total of 49 obese patients were enrolled in this study. Our findings demonstrate that ESG can be safely integrated into a conventional bariatric surgery center, with a learning curve observed after 10 cases in this study. In our series, the results showed that total body weight loss (TBWL) reached 7% at 1 month, 9% at 3 months, 14% at 6 months, 16% at 12 months, and 18.6% at 18 months. No adverse events or complications were reported in the study; however, five patients experienced procedure failures. Four of these patients underwent a repeat ESG, whereas one patient opted for surgical intervention. Conclusions ESG can be used in Asian countries, and the effectiveness of weight loss has proven to be satisfactory.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call